Changchun BCHT Biotechnology Co.
Clinical trials sponsored by Changchun BCHT Biotechnology Co., explained in plain language.
A Chinese biopharmaceutical company focused on vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a cheaper shingles booster offer same protection? Results expected Sep 2026 (estimated)
- New shingles vaccine trial aims for safer protection in adults 40+ Results expected Dec 2026 (estimated)
- New mRNA vaccine trial aims to stop genital herpes Results expected Mar 2027 (estimated)
-
New shingles vaccine trial aims for safer protection in adults 40+
Vaccine By invitation onlyThis early-stage trial tests a new shingles vaccine in 120 adults aged 40 and older. The main goal is to check safety and side effects at different doses, while also looking at how well the vaccine triggers an immune response. Participants receive either the vaccine or a placebo,…
Phase 1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Vaccine
Last updated Jun 27, 2026 13:05 UTC
-
Nasal spray flu vaccine study seeks to boost protection in kids
Vaccine By invitation onlyThis study tests a nasal spray flu vaccine in 200 people aged 3 to 17. Researchers will measure specific antibodies in the nose to see how well the vaccine works. The goal is to understand the immune response and improve flu prevention.
Phase 4 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
-
New mRNA vaccine trial aims to stop genital herpes
Vaccine By invitation onlyThis early-stage study is testing an mRNA vaccine designed to protect against genital herpes (HSV-2) in 144 healthy adults aged 18 to 55. The vaccine is given in different doses to people who have and have not been exposed to the virus before. The main goal is to check for side e…
Phase 1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Vaccine
Last updated Jun 27, 2026 08:09 UTC
-
New rabies vaccine trial aims to save lives with stronger protection
Prevention By invitation onlyThis study tests a new rabies vaccine in 3,000 healthy people aged 10 to 60. The goal is to see how well it triggers the body's defenses and if it's safe. The vaccine is given in different schedules to find the best way to prevent rabies after a possible exposure.
Phase 3 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
New rabies vaccine trial aims for safer shots
Prevention By invitation onlyThis early-stage trial is testing the safety of a freeze-dried human rabies vaccine in 80 healthy people aged 10 to 60. Participants receive the vaccine in different schedules, and researchers monitor for side effects for 30 days after the last dose. The goal is to see if the vac…
Phase 1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Prevention
Last updated Jun 27, 2026 08:11 UTC